Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 May;4(5):756-762.
doi: 10.3892/mco.2016.818. Epub 2016 Mar 10.

Outcome of patients with glioblastoma in Saudi Arabia: Single center experience

Abdullah K Altwairgi  1 , Waleed Algareeb  1 , Gaaem Yahya  1 , Ahmed M Maklad  2 , Moamen Mom Aly  3 , Wafa Al Shakweer  4 , Ali Balbaid  5 , Eyad Alsaeed  5 , Hussain Alhussain  5 , Yassir Orz  6 , Ahmed Lary  6 , Ashraf Elyamany  1
Affiliations

Outcome of patients with glioblastoma in Saudi Arabia: Single center experience

Abdullah K Altwairgi et al. Mol Clin Oncol. 2016 May.

Abstract

Glioblastoma multiforme (GBM), the most common primary brain tumor in adults, is associated with one of the worst 5 year survival rates among all human cancer types. To date, no published data are available for the outcome of this disease in Saudi Arabia. The present study performed a single-center, retrospective cohort study to evaluate the outcome of patients with GBM in Saudi Arabia. The Comprehensive Cancer Center at King Fahad Medical city (Riyadh, Saudi Arabia) was used in the present study. All adult patients (≥18 years) diagnosed with histologically proven GBM between January 2008 and December 2013 were included in the present study. A total of 90 patients were treated during the specified period. Of this, 73 (81%) patients underwent resection and 17 (19%) had biopsy only. The majority of patients (n=88; 98%) received radiotherapy (XRT): 67 (76%) with standard and 21 (24%) with hypo-fractionated dosage. Of the total patients, 65 (72%) received combined modality therapy [standard XRT concurrently with Temozolmide (TMZ)]. The 6 month progression-free survival rate was 43% for all patients and 55% for the combined modality subgroup. The median overall survival (OS) for all patients was 13.7 months. However, the median OS for patients treated with combined modality was 19.7 months. In this single-center retrospective study, the outcomes of patients with GBM were similar to those in previously reported studies. An improved outcome was associated with an improved performance status, absence of residual disease and use of adjuvant TMZ.

Keywords: brain tumor; glioblastoma multiforme; median overall survival; radiotherapy; temozolmide.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Description of study cohort.
Figure 2.
Figure 2.
Treatment exposure of patients.
Figure 3.
Figure 3.
(A) PFS and (B) OS for all patients (n=90). PFS, Progression-free survival; OS, overall survival.
Figure 4.
Figure 4.
(A) PFS and (B) OS probability over time for patients who received combined modality treatment (n=65). PFS, Progression-free survival; OS, overall survival.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Ohgaki H, Dessen P, Jourde B, Horstmann S, Nishikawa T, Di Patre PL, Burkhard C, Schüler D, Probst-Hensch NM, Maiorka PC, et al. Genetic pathways to glioblastoma: A population-based study. Cancer Res. 2004;64:6892–6899. doi: 10.1158/0008-5472.CAN-04-1337. - DOI - PubMed
    1. Ohgaki H, Kleihues P. Population-based studies on incidence, survival rates and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol. 2005;64:479–489. doi: 10.1093/jnen/64.6.479. - DOI - PubMed
    1. Bauchet L, Mathieu-Daudé H, Fabbro-Peray P, Rigau V, Fabbro M, Chinot O, Pallusseau L, Carnin C, Lainé K, Schlama A, et al. Oncological patterns of care and outcome for 952 patients with newly diagnosed glioblastoma in 2004. Neuro Oncol. 2010;12:725–735. doi: 10.1093/neuonc/noq030. - DOI - PMC - PubMed
    1. Stewart LA. Chemotherapy in adult high-grade glioma: A systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet. 2002;359:1011–1018. doi: 10.1016/S0140-6736(02)08091-1. - DOI - PubMed
    1. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987–996. doi: 10.1056/NEJMoa043330. - DOI - PubMed